Michael Scannon, MD
Procedural Dermatology · Tampa, FLNPI 1396734851
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $185,163 of the $217,711 with a category attached, or 85.0%. AbbVie accounts for 90.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $52,034 and has fallen 68.7% since, to $16,286 in 2025. Among procedural dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $586.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$196K
- Bristol Myers Squibb$9K
- Amgen$7K
- Novartis$4K
- Dermavant Sciences, Inc.$184
- Johnson & Johnson$162
- plus $1K from 20 others
Across 184 payments — averaging $3152.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$580K
What the payments were for
- Consulting fees$8,1004%
- Speaking & faculty fees$185,16385%
- Travel & lodging$16,0557%
- Food & beverage$8,2934%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 249 | $196,037 |
| Bristol Myers Squibb | 7 | $9,322 |
| Amgen | 14 | $6,920 |
| Novartis | 21 | $3,887 |
| Dermavant Sciences, Inc. | 19 | $184 |
| Johnson & Johnson | 5 | $162 |
| Revance Therapeutics, Inc. | 1 | $142 |
| E.r. Squibb & Sons, L.L.C. | 1 | $135 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $125 |
| UCB, Inc. | 3 | $104 |
| Organon | 13 | $101 |
| Sun Pharmaceutical Industries Inc. | 4 | $95 |
| Pfizer | 5 | $85 |
| Smith+Nephew | 3 | $66 |
| Arcutis Biotherapeutics, Inc. | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Biofrontera Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $40 |
| Sanofi | 1 | $30 |
| Sandoz | 1 | $24 |
| Surgenex LLC | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| LEO Pharma Inc. | 1 | $14 |
| Kerecis Limited | 2 | $14 |
| Strata Skin Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$217,711 in reported general payments places this provider in the 95th percentile of 60 procedural dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 18 | $385,124 |
| Dupixent PenDupilumab | 38 | $151,457 |
| OtezlaApremilast | 16 | $86,010 |
| Dupixent SyringeDupilumab | 15 | $63,524 |
| Tavaborole | 21 | $17,302 |
| Ivermectin | 11 | $4,546 |
| Metronidazole | 56 | $3,832 |
| Triamcinolone Acetonide | 280 | $3,565 |
| Ketoconazole | 138 | $2,969 |
| Hydrocortisone | 91 | $2,786 |
| Clobetasol Propionate | 64 | $2,468 |
| Betamethasone Dipropionate | 80 | $2,417 |
| Acitretin | 12 | $2,195 |
| Fluorouracil | 30 | $1,956 |
| Tretinoin | 24 | $1,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $6,920 | $86,01016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 procedural dermatology providers in Florida.
Other procedural dermatology in Tampa
- Linda FlynnTampa$4K
- Miloslava MicianTampa$1K
- Luis SoroFort Lauderdale$307K
- Laertes ManuelidisFort Myers$252K
- Christopher OconnellCoral Gables$76K
- Dimitry PalceskiWinter Park$23K
- Samantha MarroneOrlando$22K
- Robert BrownOrange Park$22K
- Ileana Perez-QuintairosSouth Miami$16K
- Lawrence StrongWellington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.